Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model

Area of Science:

• Neuroscience
• Regenerative Medicine
• Stem Cell Biology

Background:

• Parkinson's disease (PD) involves progressive degeneration of midbrain dopaminergic neurons.
• Induced pluripotent stem cells (iPS cells) offer a potential cell-based therapy for PD.
• Long-term primate model studies of human iPS cell-derived dopaminergic neurons are lacking.

Purpose of the Study:

• To evaluate the long-term survival, function, and safety of human iPS cell-derived dopaminergic progenitor cells in a primate model of Parkinson's disease.

Main Methods:

• Human iPS cell-derived dopaminergic progenitor cells were transplanted into MPTP-treated Macaca fascicularis primates.
• Behavioral analysis (scoring, video recording) assessed motor function.
• Histological studies examined neuronal survival, integration, and neurite extension.
• Tumorigenicity was assessed in cells sorted by the CORIN marker.
• In vivo imaging (MRI, PET) monitored cell survival, expansion, and immune response.

Main Results:

• Transplanted cells survived and differentiated into functional midbrain dopaminergic neurons.
• Significant improvements in spontaneous movement were observed in treated monkeys.
• Mature neurons extended dense neurites into the host striatum, irrespective of cell donor (PD patient or healthy).
• CORIN-sorted cells showed no tumor formation for at least two years.
• MRI and PET confirmed cell survival, expansion, and function, alongside host immune response monitoring.

Conclusions:

• Human iPS cell-derived dopaminergic progenitor cells are safe and effective in a primate PD model.
• This preclinical research supports the clinical applicability of iPS cells for Parkinson's disease therapy.